PGBD5 promotes site-specific oncogenic mutations in human tumors.
Henssen AG, Koche R, Zhuang J, Jiang E, Reed C, Eisenberg A, Still E, MacArthur IC, Rodriguez-Fos E, Gonzalez S, Puiggros M, Blackford AN, Mason CE, de Stanchina E, Gonen M, Emde AK, Shah M, Arora K, Reeves C, Socci ND, Perlman E, Antonescu CR, Roberts CWM, Steen H, Mullen E, Jackson SP, Torrents D, Weng Z, Armstrong SA, Kentsis A
Nat Genet. 2017 May 15. doi: 10.1038/ng.3866. PubMed Article
Henssen AG, Koche R, Zhuang J, Jiang E, Reed C, Eisenberg A, Still E, MacArthur IC, Rodriguez-Fos E, Gonzalez S, Puiggros M, Blackford AN, Mason CE, de Stanchina E, Gonen M, Emde AK, Shah M, Arora K, Reeves C, Socci ND, Perlman E, Antonescu CR, Roberts CWM, Steen H, Mullen E, Jackson SP, Torrents D, Weng Z, Armstrong SA, Kentsis A
Nat Genet. 2017 May 15. doi: 10.1038/ng.3866. PubMed Article
Plasmids from Article
| ID | Plasmid | Purpose |
|---|---|---|
| 78121 | pINDUCER21-PGBD5 | Lentiviral gene expression vector for doxycycline inducible PGBD5 expression |
| 80757 | pBS-EF1-IRES-NEO-Control | Transposon Reporter |
| 168053 | pRECLV103_PGBD5_B | Lentiviral expression vector for fusion of GFP with human PGBD5, NCBI: NM_001258311.1 |